Stem Cell Sector Review: Entest BioMedical

March 24, 2010 (FinancialWire) — Entest BioMedical (OTCBB: ENTB) created three bone marrow-derived stem cell lines useful for optimizing laser intensities and wavelengths in laser enhanced stem cell therapy, with the long-term potential to develop these stem cell lines to create therapies for COPD.

Other recent FinancialWire(tm) news items pertaining to the oncology and stem cell sectors today include Cell Therapeutics, Inc. (NASDAQ: CTIC) go to http://www.financialwire.net/?s=%22%28NASDAQ%3A+CTIC%29%22), BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) (go to http://www.financialwire.net/?s=%22%28NASDAQ%3A+BPAX%29%22), Myriad Genetics, Inc. (NASDAQ: MYGN) (go to http://www.financialwire.net/?s=%22%28NASDAQ%3A+MYGN%29%22), Nektar Therapeutics (NASDAQ: NKTR) (go to http://www.financialwire.net/?s=%22%28NASDAQ%3A+NKTR%29%22), Genomic Health, Inc. (NASDAQ: GHDX) (go to http://www.financialwire.net/?s=%22%28NASDAQ%3A+GHDX%29%22), Entest BioMedical, Inc. (OTCBB: ENTB) (go to http://www.financialwire.net/?s=%22%28OTCBB%3A+ENTB%29%22), and others.

Source: Zangani Investor Community (http://www.investrend.com/about/zangani).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website(http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Source of original content for this article: (http://www.zangani.com/node/4024).